Survivin, bcl-2, bax, and bcl-X gene expression in sentinel lymph nodes from melanoma patients

Angela Gradilone, Paola Gazzaniga, Diego Ribuffo, Susanna Scarpa, Emanuele Cigna, Fortunata Vasaturo, Ugo Bottoni, Daniele Innocenzi, Stefano Calvieri, Nicoló Scuderi, Luigi Frati, Anna Maria Aglianò

Research output: Contribution to journalArticle

Abstract

Purpose: The expression of apoptosis-related genes, such as survivin, bcl-2, bcl-X, and bax, has been evaluated by reverse transcriptase polymerase chain reaction (RT-PCR) and by immunohistochemistry in sentinel lymph nodes (SLNs) from melanoma patients and then correlated to the outcome of patients. Patients and Methods: Thirty-six SLNs were examined. After RNA extraction, an RT-PCR followed by Southern blot hybridization was performed to detect survivin, bcl-2, bcl-X, and bax mRNA. bcl-2, survivin, and bax gene expression was evaluated, whenever possible, also by immunohistochemistry at the protein level. Results: We found a significant correlation (P <.005) between survivin expression and outcome of patients; in f act, 61.5% of patients expressing survivin gene progressed or died because of the disease, whereas 38.5% are currently disease-free. Among patients negative for survivin expression, 100% are disease-free after a median follow-up time of 52.9 months. We did not find a significant correlation between bcl-2, bax, and bcl-X gene expression and outcome of patients. In fact, these genes were found equally expressed in patients with disease progression and in disease-free patients. Conclusion: Our findings show a variable expression of apoptosis-related genes in SLNs of melanoma patients; more interestingly, we found that survivin expression correlates to outcome of patients in a statistically significant way, whereas the expression of other genes, such as bcl-2, bax, and bcl-X, did not seem to correlate to progression of disease. We suggest that the detection of survivin gene expression by RT-PCR in SLNs may be a useful prognostic indicator.

Original languageEnglish
Pages (from-to)306-312
Number of pages7
JournalJournal of Clinical Oncology
Volume21
Issue number2
DOIs
Publication statusPublished - Jan 15 2003

Fingerprint

Melanoma
Gene Expression
Reverse Transcriptase Polymerase Chain Reaction
Genes
Disease Progression
Sentinel Lymph Node
Immunohistochemistry
Apoptosis
Southern Blotting
RNA
Messenger RNA

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Gradilone, A., Gazzaniga, P., Ribuffo, D., Scarpa, S., Cigna, E., Vasaturo, F., ... Aglianò, A. M. (2003). Survivin, bcl-2, bax, and bcl-X gene expression in sentinel lymph nodes from melanoma patients. Journal of Clinical Oncology, 21(2), 306-312. https://doi.org/10.1200/JCO.2003.08.066

Survivin, bcl-2, bax, and bcl-X gene expression in sentinel lymph nodes from melanoma patients. / Gradilone, Angela; Gazzaniga, Paola; Ribuffo, Diego; Scarpa, Susanna; Cigna, Emanuele; Vasaturo, Fortunata; Bottoni, Ugo; Innocenzi, Daniele; Calvieri, Stefano; Scuderi, Nicoló; Frati, Luigi; Aglianò, Anna Maria.

In: Journal of Clinical Oncology, Vol. 21, No. 2, 15.01.2003, p. 306-312.

Research output: Contribution to journalArticle

Gradilone, A, Gazzaniga, P, Ribuffo, D, Scarpa, S, Cigna, E, Vasaturo, F, Bottoni, U, Innocenzi, D, Calvieri, S, Scuderi, N, Frati, L & Aglianò, AM 2003, 'Survivin, bcl-2, bax, and bcl-X gene expression in sentinel lymph nodes from melanoma patients', Journal of Clinical Oncology, vol. 21, no. 2, pp. 306-312. https://doi.org/10.1200/JCO.2003.08.066
Gradilone, Angela ; Gazzaniga, Paola ; Ribuffo, Diego ; Scarpa, Susanna ; Cigna, Emanuele ; Vasaturo, Fortunata ; Bottoni, Ugo ; Innocenzi, Daniele ; Calvieri, Stefano ; Scuderi, Nicoló ; Frati, Luigi ; Aglianò, Anna Maria. / Survivin, bcl-2, bax, and bcl-X gene expression in sentinel lymph nodes from melanoma patients. In: Journal of Clinical Oncology. 2003 ; Vol. 21, No. 2. pp. 306-312.
@article{b73ef563f74c46249dafc876cedf0fcc,
title = "Survivin, bcl-2, bax, and bcl-X gene expression in sentinel lymph nodes from melanoma patients",
abstract = "Purpose: The expression of apoptosis-related genes, such as survivin, bcl-2, bcl-X, and bax, has been evaluated by reverse transcriptase polymerase chain reaction (RT-PCR) and by immunohistochemistry in sentinel lymph nodes (SLNs) from melanoma patients and then correlated to the outcome of patients. Patients and Methods: Thirty-six SLNs were examined. After RNA extraction, an RT-PCR followed by Southern blot hybridization was performed to detect survivin, bcl-2, bcl-X, and bax mRNA. bcl-2, survivin, and bax gene expression was evaluated, whenever possible, also by immunohistochemistry at the protein level. Results: We found a significant correlation (P <.005) between survivin expression and outcome of patients; in f act, 61.5{\%} of patients expressing survivin gene progressed or died because of the disease, whereas 38.5{\%} are currently disease-free. Among patients negative for survivin expression, 100{\%} are disease-free after a median follow-up time of 52.9 months. We did not find a significant correlation between bcl-2, bax, and bcl-X gene expression and outcome of patients. In fact, these genes were found equally expressed in patients with disease progression and in disease-free patients. Conclusion: Our findings show a variable expression of apoptosis-related genes in SLNs of melanoma patients; more interestingly, we found that survivin expression correlates to outcome of patients in a statistically significant way, whereas the expression of other genes, such as bcl-2, bax, and bcl-X, did not seem to correlate to progression of disease. We suggest that the detection of survivin gene expression by RT-PCR in SLNs may be a useful prognostic indicator.",
author = "Angela Gradilone and Paola Gazzaniga and Diego Ribuffo and Susanna Scarpa and Emanuele Cigna and Fortunata Vasaturo and Ugo Bottoni and Daniele Innocenzi and Stefano Calvieri and Nicol{\'o} Scuderi and Luigi Frati and Aglian{\`o}, {Anna Maria}",
year = "2003",
month = "1",
day = "15",
doi = "10.1200/JCO.2003.08.066",
language = "English",
volume = "21",
pages = "306--312",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "2",

}

TY - JOUR

T1 - Survivin, bcl-2, bax, and bcl-X gene expression in sentinel lymph nodes from melanoma patients

AU - Gradilone, Angela

AU - Gazzaniga, Paola

AU - Ribuffo, Diego

AU - Scarpa, Susanna

AU - Cigna, Emanuele

AU - Vasaturo, Fortunata

AU - Bottoni, Ugo

AU - Innocenzi, Daniele

AU - Calvieri, Stefano

AU - Scuderi, Nicoló

AU - Frati, Luigi

AU - Aglianò, Anna Maria

PY - 2003/1/15

Y1 - 2003/1/15

N2 - Purpose: The expression of apoptosis-related genes, such as survivin, bcl-2, bcl-X, and bax, has been evaluated by reverse transcriptase polymerase chain reaction (RT-PCR) and by immunohistochemistry in sentinel lymph nodes (SLNs) from melanoma patients and then correlated to the outcome of patients. Patients and Methods: Thirty-six SLNs were examined. After RNA extraction, an RT-PCR followed by Southern blot hybridization was performed to detect survivin, bcl-2, bcl-X, and bax mRNA. bcl-2, survivin, and bax gene expression was evaluated, whenever possible, also by immunohistochemistry at the protein level. Results: We found a significant correlation (P <.005) between survivin expression and outcome of patients; in f act, 61.5% of patients expressing survivin gene progressed or died because of the disease, whereas 38.5% are currently disease-free. Among patients negative for survivin expression, 100% are disease-free after a median follow-up time of 52.9 months. We did not find a significant correlation between bcl-2, bax, and bcl-X gene expression and outcome of patients. In fact, these genes were found equally expressed in patients with disease progression and in disease-free patients. Conclusion: Our findings show a variable expression of apoptosis-related genes in SLNs of melanoma patients; more interestingly, we found that survivin expression correlates to outcome of patients in a statistically significant way, whereas the expression of other genes, such as bcl-2, bax, and bcl-X, did not seem to correlate to progression of disease. We suggest that the detection of survivin gene expression by RT-PCR in SLNs may be a useful prognostic indicator.

AB - Purpose: The expression of apoptosis-related genes, such as survivin, bcl-2, bcl-X, and bax, has been evaluated by reverse transcriptase polymerase chain reaction (RT-PCR) and by immunohistochemistry in sentinel lymph nodes (SLNs) from melanoma patients and then correlated to the outcome of patients. Patients and Methods: Thirty-six SLNs were examined. After RNA extraction, an RT-PCR followed by Southern blot hybridization was performed to detect survivin, bcl-2, bcl-X, and bax mRNA. bcl-2, survivin, and bax gene expression was evaluated, whenever possible, also by immunohistochemistry at the protein level. Results: We found a significant correlation (P <.005) between survivin expression and outcome of patients; in f act, 61.5% of patients expressing survivin gene progressed or died because of the disease, whereas 38.5% are currently disease-free. Among patients negative for survivin expression, 100% are disease-free after a median follow-up time of 52.9 months. We did not find a significant correlation between bcl-2, bax, and bcl-X gene expression and outcome of patients. In fact, these genes were found equally expressed in patients with disease progression and in disease-free patients. Conclusion: Our findings show a variable expression of apoptosis-related genes in SLNs of melanoma patients; more interestingly, we found that survivin expression correlates to outcome of patients in a statistically significant way, whereas the expression of other genes, such as bcl-2, bax, and bcl-X, did not seem to correlate to progression of disease. We suggest that the detection of survivin gene expression by RT-PCR in SLNs may be a useful prognostic indicator.

UR - http://www.scopus.com/inward/record.url?scp=0037440238&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037440238&partnerID=8YFLogxK

U2 - 10.1200/JCO.2003.08.066

DO - 10.1200/JCO.2003.08.066

M3 - Article

C2 - 12525523

AN - SCOPUS:0037440238

VL - 21

SP - 306

EP - 312

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 2

ER -